pegvisomant 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
5015 218620-50-9

Description:

MoleculeDescription

Synonyms:

  • B-2036 PEG
  • pegvisomant
  • somavert
  • pegvisomant (genetical recombination)
  • B2036-PEG
  • trovert
is a genetically engineered analogue of human growth hormone that functions as a growth hormone-receptor antagonist; used to treat Acromegaly
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
10 mg P

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Nov. 13, 2002 EMA
March 25, 2003 FDA PHARMACIA AND UPJOHN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Insulin-like growth factor increased 604.23 27.71 95 3693 723 50600613
Blood growth hormone increased 147.75 27.71 26 3762 411 50600925
Needle issue 103.13 27.71 33 3755 7242 50594094
Lipohypertrophy 89.58 27.71 18 3770 595 50600741
Pituitary tumour 77.80 27.71 17 3771 848 50600488
Pituitary tumour benign 70.47 27.71 18 3770 1763 50599573
Insulin-like growth factor decreased 66.88 27.71 13 3775 361 50600975
Product dose omission issue 63.04 27.71 73 3715 183765 50417571
Injection site hypertrophy 59.15 27.71 9 3779 53 50601283
Pituitary tumour recurrent 57.55 27.71 9 3779 65 50601271
Insulin-like growth factor abnormal 56.34 27.71 7 3781 4 50601332
Injection site mass 55.80 27.71 26 3762 15654 50585682
Glycosylated haemoglobin increased 55.28 27.71 23 3765 10583 50590753
Lipodystrophy acquired 50.47 27.71 13 3775 1316 50600020
Poor quality product administered 49.20 27.71 15 3773 2804 50598532
Headache 49.07 27.71 113 3675 506422 50094914
Injection site pain 46.47 27.71 49 3739 110975 50490361
Rectal polyp 44.42 27.71 11 3777 950 50600386
Neoplasm progression 43.18 27.71 27 3761 29130 50572206
Sensitisation 38.98 27.71 11 3777 1571 50599765
Diabetes mellitus 38.91 27.71 31 3757 49002 50552334
Product use issue 37.76 27.71 51 3737 149424 50451912
Change of bowel habit 37.67 27.71 11 3777 1773 50599563
Injection site discomfort 37.03 27.71 13 3775 3777 50597559
Intestinal haemorrhage 35.30 27.71 12 3776 3168 50598168
Injection site bruising 35.21 27.71 26 3762 36742 50564594
Blood glucose increased 32.55 27.71 33 3755 71291 50530045
Polyp 32.17 27.71 13 3775 5549 50595787
Bone density increased 30.06 27.71 7 3781 465 50600871
Blood glucose decreased 29.85 27.71 18 3770 18193 50583143

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Insulin-like growth factor increased 656.11 33.24 107 2225 1004 29571191
Blood growth hormone increased 178.62 33.24 29 2303 259 29571936
Product dose omission issue 63.95 33.24 56 2276 96327 29475868
Pituitary tumour benign 61.98 33.24 14 2318 772 29571423
Needle issue 60.29 33.24 20 2312 4663 29567532
Blood testosterone decreased 55.49 33.24 18 2314 3912 29568283
Headache 51.98 33.24 66 2266 173941 29398254
Pituitary tumour 50.73 33.24 11 2321 502 29571693
Cholelithiasis 50.26 33.24 26 2306 18646 29553549
Insulin-like growth factor abnormal 47.63 33.24 6 2326 4 29572191
Product use issue 44.69 33.24 35 2297 51409 29520786
Injection site bruising 43.95 33.24 18 2314 7562 29564633
Insulin-like growth factor decreased 39.50 33.24 8 2324 261 29571934
Glycosylated haemoglobin increased 37.01 33.24 17 2315 9409 29562786
Arthralgia 37.00 33.24 50 2282 139567 29432628
Injection site pain 36.96 33.24 26 2306 32420 29539775
Pituitary tumour recurrent 36.13 33.24 6 2326 62 29572133
Blood testosterone free decreased 35.39 33.24 6 2326 71 29572124

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Insulin-like growth factor increased 1203.66 29.10 195 5749 1457 64491331
Blood growth hormone increased 295.61 29.10 51 5893 571 64492217
Needle issue 158.61 29.10 51 5893 9221 64483567
Product dose omission issue 140.46 29.10 127 5817 194620 64298168
Pituitary tumour 123.81 29.10 27 5917 1079 64491709
Pituitary tumour benign 109.10 29.10 28 5916 2265 64490523
Insulin-like growth factor abnormal 97.38 29.10 13 5931 16 64492772
Insulin-like growth factor decreased 93.41 29.10 19 5925 539 64492249
Glycosylated haemoglobin increased 90.28 29.10 39 5905 15980 64476808
Pituitary tumour recurrent 84.39 29.10 14 5930 121 64492667
Headache 83.51 29.10 163 5781 529304 63963484
Product use issue 82.83 29.10 85 5859 151630 64341158
Lipohypertrophy 81.24 29.10 18 5926 774 64492014
Injection site hypertrophy 80.01 29.10 12 5932 49 64492739
Injection site pain 76.88 29.10 71 5873 111337 64381451
Injection site mass 68.72 29.10 33 5911 17237 64475551
Blood testosterone decreased 63.60 29.10 18 5926 2107 64490681
Neoplasm progression 63.09 29.10 42 5902 40922 64451866
Injection site bruising 57.72 29.10 38 5906 36335 64456453
Poor quality product administered 52.16 29.10 17 5927 3198 64489590
Blood glucose increased 51.74 29.10 54 5890 98019 64394769
Low density lipoprotein increased 47.42 29.10 20 5924 7720 64485068
Polyp 46.83 29.10 19 5925 6654 64486134
Cholelithiasis 45.68 29.10 36 5908 45470 64447318
Blood thyroid stimulating hormone decreased 44.08 29.10 17 5927 5213 64487575
Bone density increased 43.14 29.10 10 5934 527 64492261
Diabetes mellitus 41.28 29.10 40 5904 66434 64426354
Injection site discomfort 40.12 29.10 15 5929 4226 64488562
Arthralgia 39.38 29.10 109 5835 442151 64050637
Rectal polyp 38.98 29.10 11 5933 1273 64491515
Blood testosterone free decreased 37.41 29.10 6 5938 41 64492747
Blood pressure increased 37.09 29.10 61 5883 172491 64320297
Fatigue 36.83 29.10 151 5793 748579 63744209
Sensitisation 35.74 29.10 11 5933 1720 64491068
Neoplasm 32.80 29.10 15 5929 7016 64485772
Blood prolactin decreased 32.53 29.10 7 5937 262 64492526
Change of bowel habit 32.04 29.10 11 5933 2427 64490361
Off label use 31.36 29.10 128 5816 632678 63860110
Gallbladder disorder 29.98 29.10 19 5925 17011 64475777
Growth hormone-producing pituitary tumour 29.39 29.10 5 5939 51 64492737
Blood glucose decreased 29.21 29.10 21 5923 23102 64469686

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC H01AX01 SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES
Other anterior pituitary lobe hormones and analogues
FDA MoA N0000010267 Growth Hormone Receptor Antagonists
FDA EPC N0000190119 Growth Hormone Receptor Antagonist

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Acromegaly indication 74107003 DOID:2449




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Growth hormone receptor GPCR ANTAGONIST DRUG LABEL DRUG LABEL

External reference:

IDSource
D05394 KEGG_DRUG
4021390 VUID
N0000148808 NUI
4021390 VANDF
CHEMBL1201515 ChEMBL_ID
C406545 MESH_SUPPLEMENTAL_RECORD_UI
7485 IUPHAR_LIGAND_ID
7941 INN_ID
DB00082 DRUGBANK_ID
N824AOU5XV UNII
278739 RXNORM
17174 MMSL
46371 MMSL
d04854 MMSL
409201000 SNOMEDCT_US
409204008 SNOMEDCT_US
C0913469 UMLSCUI
009929 NDDF

Pharmaceutical products:

None